Leap Therapeutics Q3 2025 Earnings Report

Leap Therapeutics EPS Results

• Actual EPS: -$0.08
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Leap Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Leap Therapeutics Announcement Details

• Quarter: Q3 2025
• Date: 11/12/2025
• Time: Before Market Opens
• Conference Call Date: Wednesday, November 12, 2025
• Conference Call Time: 7:00AM ET

Leap Therapeutics (NASDAQ:LPTX) (NASDAQ: LPTX) is a clinical-stage biotechnology company focused on the discovery and development of targeted therapies and immuno-oncology treatments for patients with cancer. The company advances candidates through preclinical and clinical development with the goal of addressing unmet needs in solid tumors by modulating tumor biology and antitumor immune responses.

Leap’s research and development strategy emphasizes biologic therapeutic agents and combination approaches intended to enhance efficacy in difficult-to-treat cancers. The company pursues clinical programs designed to generate proof-of-concept data and to support regulatory interactions, and it seeks strategic collaborations to accelerate development and broaden access to its investigational therapies.

As a development-stage company, Leap conducts clinical trials and engages with academic and industry partners to progress its pipeline. Public filings and company communications provide additional details on specific programs, trial designs and partnership arrangements for investors and other stakeholders interested in the company’s development trajectory.